UNIVERSITY OF IOWA INSTITUTIONAL CALGB GRANT

这个应用程序是为了支持我们参与多- 多学科、多机构合作的团体临床 癌症和急性白血病B组的试验自加入 CALGB六个月前，我们已经发展成为积极的参与者 第二阶段和第三阶段研究和配套研究都强调 实验室调查。多学科研究的新进展 小组协助将这些模式在 爱荷华大学本身。合作组成员身份允许 爱荷华大学调查人员在未来5年将重点放在 创新的小型临床试验(1/2期类型试验 适用于单个机构)，同时参与 受控、随机的第三阶段试验在一年内不可行 一家医院。此外，CALGB的活动已经 在爱荷华州大学开展的利用生物学 设置中的响应修饰符，其中受控比较可以 被创造出来。 我们在下一个资助期的具体目标包括启动 霍奇金氏病和非霍奇金氏病抢救治疗的团体试验 对一线化疗耐药的淋巴瘤患者使用强化治疗 治疗和自体骨髓移植支持，试验使用 爱荷华大学免疫学实验室检测 LAK细胞活性和其他免疫学参数，试验使用 辐射敏感剂(如氯硝胺)或支气管镜 辐射作为放射治疗的创新，以及使用 分化试剂(13-顺式维甲酸、维生素D3)基于 爱荷华大学的I/II阶段试验结果。穿过 我们希望通过参与集体试验来推进 整个CALGB。通过试点研究(如MOPLEC 霍奇金氏病或淋巴瘤的β-干扰素和IL-2)我们将 为未来的对照试验帮助开发新的疗法。穿过 与实验室相关的配套研究，我们将推进基础 其他CALGB机构的科学项目。多种多样- CALGB的纪律计划将在接下来的时间里做出贡献 5年来对研究员和住院医生进行培训 爱荷华大学。通过3家子公司的发展 计划，将促进高质量的多学科癌症护理 在爱荷华州，这是一个农村州，几乎没有大型癌症项目。我们的应计项目 每年应该有大约100名来自该大学的患者 爱荷华州医院系统，每年增加20名患者 来自我们的3家附属公司。

This application is to support our participation in the multi- disciplinary and multi-institutional cooperative group clinical trials of Cancer and Acute Leukemia Group B. Since joining the CALGB 6 months ago, we have developed into active participants in both phase 2 and 3 studies and companion studies emphasizing laboratory investigation. The multidisciplinary studies of the group assist in bringing together these modalities at the University of Iowa itself. Cooperative group membership allows the University of Iowa investigators over the next 5 years to focus on innovative, small clinical trials (Phase 1/2 type trials appropriate for a single institution) while participating in controlled, randomized phase III trials not feasible within a single hospital. Further, the activities of the CALGB have initiated research at the University of Iowa utilizing biological response modifiers in a setting in which controlled comparisons can be made. Our specific goals in the next grant period include initiating for the group trials in salvage therapy for Hodgkin's and non-Hodgkin's lymphoma patients resistant to lst line therapies using intensive therapy and autologous bone marrow transplant support, trials using the immunology laboratory of the University of Iowa for assay of LAK cell activity and other immunologic parameters, trials using radiation sensitizers (such as Lonidamine) or endobronchial radiation as innovations in radiation therapy, and trials using differentiating agents (13-cis Retinoic Acid, Vitamin D3) based on phase I/II trial results at the University of Iowa. Through participation in groups trials we hope to advance the programs of the entire CALGB. Through pilot studies (such as MOPLEC for Hodgkin's disease or beta-Interferon and IL-2 for lymphoma) we will help develop newer therapies for future controlled trials. Through laboratory related companion studies, we will advance the basic science programs of other CALGB institutions. The multi- disciplinary programs of the CALGB will contribute over the next 5 years to the training of both fellows and residents at the University of Iowa. Through the development of 3 affiliate programs, quality multidisciplinary cancer care will be fostered in Iowa, a rural state with few large cancer programs. Our accrual should be approximately 100 patients per year from the University of Iowa Hospital system and 20 more patients in addition per year from our 3 affiliates.